Venture Funding Deals: Semma, Arcus Raise $100m-Plus For Cancer, Diabetes Therapies
Semma's $114m Series B round and a $107m Series C for Arcus top November's list of biopharmaceutical venture capital deals. Forty Seven, Medeor and Tricida also closed sizeable rounds.
You may also be interested in...
Private Company Edition: GHO Capital will invest €975m in pharmaceutical and other opportunities in Europe, but Wellington’s $393m fund is focused on drug discovery and development. Also, Avidity raises $100m and Werewolf launches with $56m.
Clinical studies by resTORbio into age-related immunosenescence attracts investors keen to advance a potential new class of immunotherapy agents.
Merck KGaA and Artios penned a global three-year strategic research collaboration to discover and develop multiple precision oncology drugs. The deal could be worth close to $7bn for four-year-old Artios. AstraZeneca announced a definitive agreement to acquire public rare disease drug developer Alexion for approximately $39bn. This was 2020’s largest M&A. Financing reached $28bn in biopharma, $879m in device, and $2.4bn in diagnostics.